Skip to content
value.today

Tricida: financial analysis

Ratios worked out from 6 fiscal years of Tricida's statements, compared with 665 companies in Biotechnology.

The newest statement on file is for fiscal 2021. The figures below describe that year, not Tricida today.

Return on equity, 2021
-323.7%
Biotechnology: -61.0%
Debt to equity, 2021
0.00×
Biotechnology: 0.26×

Tricida scorecard#

Passes 3 of the 11 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.44 vs -5.29Diluted EPS -3.44 in fiscal 2021 against -5.29 the year before (report's currency).
    • ✗Net income higher than five years earlier-$177 M-$177 M in fiscal 2021 against -$29 M in 2016.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$177 MNet income -$177 M in fiscal 2021.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2021.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-323.7%-323.7% in fiscal 2021.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.94 at the end of fiscal 2021.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2021.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $21 M at the end of fiscal 2021.
    • ✗Operating income covers interest five times-8.7×Operating income -8.7 times interest in fiscal 2021.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.5%Diluted shares up 2.5% in fiscal 2021.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2021 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • More cash than debt: net cash of $21 million.

Worth a look

  • Net loss of $177 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$140 million.
  • Operating income covers the interest bill only -8.7 times.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

2of 7(2 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsyes
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin rosenot on file
  • Asset turnover rosenot on file

Profitability#

Tricida: profitability by fiscal year
Fiscal yearTrend20212020201920182017Median of peersAhead of
Return on equity-323.7%-142.1%-77.1%-193.1%—-61.0%5%
Return on assets-67.9%-73.2%-57.1%-64.6%-58.5%-44.4%32%

Financial strength#

Tricida: financial strength by fiscal year
Fiscal yearTrend20212020201920182017Median of peersAhead of
Debt to equity0.00×0.70×0.22×0.20×—0.26×82%
Net debt$-21 M$-61 M$40 M$1 M$-10 M$-16 M55%
Interest cover-8.69×-13.66×-31.15×-32.99×—-22.77×66%
Current ratio4.94×9.17×7.87×16.51×6.19×4.39×54%
Equity share of assets0.1%31.0%71.0%78.5%-124.8%64.7%17%

Cash#

Tricida: cash by fiscal year
Fiscal yearTrend20212020201920182017Median of peersAhead of
Free cash flow$-140 M$-233 M$-131 M$-96 M$-41 M$-40 M18%

Shareholder returns#

Tricida: shareholder returns by fiscal year
Fiscal yearTrend20212020201920182017Median of peersAhead of
Change in share count2.5%————17.3%80%

How each figure is worked out#

Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Change in share count
Diluted shares against the year before. Negative: fewer shares.

Source: Tricida's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Tricida is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Tricida